The intricate interface between immune system and metabolism

Trends in Immunology

Volumn 25, Issue 4, 2004, Pages 193-200

  Matarese, Giuseppe ^a   La Cava, Antonio ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA INTERMEDIN; ALPHA2 GLYCOPROTEIN; ANTIDIABETIC AGENT; ARACHIDIC ACID; ATTRACTIN; CD1 ANTIGEN; CD28 ANTIGEN; CORTICOTROPIN RELEASING FACTOR; FC RECEPTOR; GAMMA INTERFERON; GLUCOSE; GLUCOSE TRANSPORTER; IMMUNOSUPPRESSIVE AGENT; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; LEPTIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NEUROPEPTIDE; NEUROTRANSMITTER; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIRINIXIC ACID; PROTEIN; PROTEIN MAHOGANY; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ZINC ALPHA2 GLYCOPROTEIN;

ALLERGIC ENCEPHALOMYELITIS; ANOREXIA; ARTHRITIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BASAL METABOLIC RATE; CATABOLISM; CELLULAR IMMUNITY; COLITIS; CYTOKINE RELEASE; DISEASE COURSE; ENERGY; ENERGY EXPENDITURE; FOOD INTAKE; GENETIC DISORDER; GLUCOSE METABOLISM; GLYCOLYSIS; HEPATITIS; HOMEOSTASIS; IMMUNE SYSTEM; IMMUNOSURVEILLANCE; INFERTILITY; INFLAMMATION; INSULIN RESISTANCE; LIPID METABOLISM; LIPOLYSIS; MAST CELL; METABOLISM; MULTIGENE FAMILY; NEUROENDOCRINE SYSTEM; NONHUMAN; NUTRITION; REVIEW; STARVATION; T LYMPHOCYTE ACTIVATION;

ANIMALS; CYTOKINES; ENERGY METABOLISM; GLUCOSE; HORMONES; HUMANS; IMMUNE SYSTEM; IMMUNE TOLERANCE; LYMPHOCYTE ACTIVATION; MODELS, BIOLOGICAL; NEUROPEPTIDES; T-LYMPHOCYTES; TRANSCRIPTION FACTORS;

EID: 1642315558     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2004.02.009     Document Type: Review

References (63)

1. Heber D. Starvation and nutritional therapy. DeGroot L.J., Jameson J.L. Endocrinology. 4th edn:2001;642-653 W.B. Saunders Company.
2. Kennedy G.C. The role of depot fat in the hypothalamic control of food intake in the rat. Proc. R. Soc. Lond. B. Biol. Sci. 140:1953;578-596.
3. Matarese G., et al. Balancing susceptibility to infection and autoimmunity: a role for leptin? Trends Immunol. 23:2002;182-187.
4. Haddad J.J., et al. Cytokines and neuro-immune-endocrine interactions: a role for the hypothalamic-pituitary-adrenal revolving axis. J. Neuroimmunol. 133:2002;1-19.
5. La Cava A., Sarvetnick N. The role of cytokines in autoimmunity. Curr. Dir. Autoimmun. 1:1999;56-71.
6. Bruun J.M., et al. Effects of proinflammatory cytokines and chemokines on leptin production in human adipose tissue in vitro. Mol. Cell. Endocrinol. 190:2002;91-99.
7. Gerhardt C.C., et al. Chemokines control fat accumulation and leptin secretion by cultured human adipocytes. Mol. Cell. Endocrinol. 175:2001;81-92.
8. Friedman J.M., Halaas J.L. Leptin and the regulation of body weight in mammals. Nature. 395:1998;763-770.
9. La Cava A., et al. Leptin-based immune intervention: current status and future directions. Curr. Opin. Invest. Drugs. 4:2003;1327-1332.
10. Fantuzzi G., Faggioni R. Leptin in the regulation of immunity, inflammation, and hematopoiesis. J. Leukoc. Biol. 68:2000;437-446.
11. Moore S.I., et al. Leptin modulates neutrophil phagocytosis of Klebsiella pneumoniae. Infect. Immun. 71:2003;4182-4185.
12. Caldefie-Chezet F., et al. Leptin regulates functional capacities of polymorphonuclear neutrophils. Free Radic. Res. 37:2003;809-814.
13. Lord G.M., et al. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature. 394:1998;897-901.
14. Farooqi S., et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J. Clin. Invest. 110:2002;1093-1103.
15. Sanna V., et al. Leptin surge precedes onset of autoimmune encephalomyelitis and correlates with development of pathogenic T cell responses. J. Clin. Invest. 111:2003;241-250.
16. Busso N., et al. Leptin signaling deficiency impairs humoral and cellular immune responses and attenuates experimental arthritis. J. Immunol. 168:2002;875-882.
17. Siegmund B., et al. Leptin: a pivotal mediator of intestinal inflammation in mice. Gastroenterology. 122:2002;2011-2025.
18. Faggioni R., et al. Leptin-deficient (ob/ob) mice are protected from T cell-mediated hepatotoxicity: role of tumor necrosis factor α and IL-18. Proc. Natl. Acad. Sci. U. S. A. 97:2000;2367-2372.
19. Matarese G., et al. Leptin potentiates experimental autoimmune encephalomyelitis in SJL female mice and confers susceptibility to males. Eur. J. Immunol. 31:2001;1324-1332.
20. Matarese G., et al. Leptin accelerates autoimmune diabetes in female NOD mice. Diabetes. 51:2002;1356-1361.
21. Stentz F.B., Kitabchi A.E. Activated T lymphocytes in type 2 diabetes: implications from in vitro studies. Curr. Drug Targets. 4:2003;493-503.
22. Dandona, P. et al. Inflammation as the link between insulin resistance, obesity and diabetes. Trends Immunol. 25, 4-7.
23. Matsuki T., et al. IL-1 plays an important role in lipid metabolism by regulating insulin levels under physiological conditions. J. Exp. Med. 198:2003;877-888.
24. Juge-Aubry C.E., et al. Adipose tissue is a major source of interleukin-1 receptor antagonist: upregulation in obesity and inflammation. Diabetes. 52:2003;1104-1110.
25. Wallenius V., et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat. Med. 8:2002;75-79.
26. Eugster H.P., et al. IL-6-deficient mice resist myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. Eur. J. Immunol. 28:1998;2178-2187.
27. Nowell M.A., et al. Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. J. Immunol. 171:2003;3202-3209.
28. O'Shea J.J., et al. Cytokines and autoimmunity. Nat. Rev. Immunol. 2:2002;37-45.
29. La Cava A. Cytokines and autoimmune rheumatic diseases. Int. J. Adv. Rheumatol. 1:2003;10-19.
30. Warne J.P. Tumour necrosis factor α: a key regulator of adipose tissue mass. J. Endocrinol. 177:2003;351-355.
31. Xu H., et al. Transmembrane tumor necrosis factor (TNF)-α inhibits adipocyte differentiation by selectively activating TNF receptor 1. J. Biol. Chem. 274:1999;26287-26295.
32. Fruhbeck G., et al. The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am. J. Physiol. Endocrinol. Metab. 280:2001;E827-E847.
33. Arsenijevic D., et al. A role for interferon-γ in the hypermetabolic response to murine toxoplasmosis. Eur. Cytokine Netw. 12:2001;518-527.
34. Arsenijevic D., et al. Differential roles of tumor necrosis factor-α and interferon-γ in mouse hypermetabolic and anorectic responses induced by LPS. Eur. Cytokine Netw. 11:2000;662-668.
35. Lu X.Y., et al. Interaction between α-melanocyte-stimulating hormone and corticotropin-releasing hormone in the regulation of feeding and hypothalamo-pituitary-adrenal responses. J. Neurosci. 23:2003;7863-7872.
36. Makrigiannakis A., et al. Corticotropin-releasing hormone promotes blastocyst implantation and early maternal tolerance. Nat. Immunol. 2:2001;1018-1024.
37. Taylor A.W., et al. Neuropeptide regulation of immunity. The immunosuppressive activity of α-melanocyte-stimulating hormone. Ann. N. Y. Acad. Sci. 917:2000;239-247.
38. Venihaki M., et al. Corticotropin-releasing hormone regulates IL-6 expression during inflammation. J. Clin. Invest. 108:2001;1159-1166.
39. Farooqi I.S., et al. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N. Engl. J. Med. 348:2003;1085-1095.
40. Adachi S., et al. Receptor-mediated modulation of murine mast cell function by α-melanocyte stimulating hormone. J. Immunol. 163:1999;3363-3368.
41. Namba K., et al. Induction of regulatory T cells by the immunomodulating cytokines α-melanocyte-stimulating hormone and transforming growth factor-β2. J. Leukoc. Biol. 72:2002;946-952.
42. Neumann Andersen G., et al. MC(1) receptors are constitutively expressed on leucocyte subpopulations with antigen presenting and cytotoxic functions. Clin. Exp. Immunol. 126:2001;441-446.
43. Rathmell J.C., et al. In the absence of extrinsic signals, nutrient utilization by lymphocytes is insufficient to maintain either cell size or viability. Mol. Cell. 6:2000;683-692.
44. June C.H., et al. The B7 and CD28 receptor families. Immunol. Today. 15:1994;321-331.
45. Frauwirth K.A., et al. The CD28 signaling pathway regulates glucose metabolism. Immunity. 16:2002;769-777.
46. Grohmann U., et al. Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol. 24:2003;242-248.
47. Dong Z.M., et al. A new class of obesity genes encodes leukocyte adhesion receptors. Proc. Natl. Acad. Sci. U. S. A. 94:1997;7526-7530.
48. Duke-Cohan J.S., et al. Serum high molecular weight dipeptidyl peptidase IV (CD26) is similar to a novel antigen DPPT-L released from activated T cells. J. Immunol. 156:1996;1714-1721.
49. Gunn T.M., et al. The mouse mahogany locus encodes a transmembrane form of human attractin. Nature. 398:1999;152-156.
50. Nagle D.L., et al. The mahogany protein is a receptor involved in suppression of obesity. Nature. 398:1999;148-152.
51. Kennedy M.W., et al. Hydrophobic ligand binding by Zn-α 2-glycoprotein, a soluble fat-depleting factor related to major histocompatibility complex proteins. J. Biol. Chem. 276:2001;35008-35013.
52. Sanchez L.M., et al. Biochemical characterization and crystalization of human Zn-α2-glycoprotein, a soluble class I major histocompatibility complex homolog. Proc. Natl. Acad. Sci. U. S. A. 94:1997;4626-4630.
53. Berger J., Moller D.E. The mechanisms of action of PPARs. Annu. Rev. Med. 53:2002;409-435.
54. Jones D.C., et al. Peroxisome proliferator-activated receptor α negatively regulates T-bet transcription through suppression of p38 mitogen-activated protein kinase activation. J. Immunol. 171:2003;196-203.
55. Cunard R., et al. WY14,643, a PPAR α ligand, has profound effects on immune responses in vivo. J. Immunol. 169:2002;6806-6812.
56. Diab A., et al. Peroxisome proliferator-activated receptor-γ agonist 15-deoxy-Δ(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. J. Immunol. 168:2002;2508-2515.
57. Clark R.B., et al. The nuclear receptor PPAR γ and immunoregulation: PPAR γ mediates inhibition of helper T cell responses. J. Immunol. 164:2000;1364-1371.
58. Kawahito Y., et al. 15-deoxy-Δ(12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J. Clin. Invest. 106:2000;189-197.
59. Su C.G., et al. A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response. J. Clin. Invest. 104:1999;383-389.
60. Ricote M., et al. Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc. Natl. Acad. Sci. U. S. A. 95:1998;7614-7619.
61. Gilroy D.W., et al. Inducible cyclooxygenase may have anti-inflammatory properties. Nat. Med. 5:1999;698-701.
62. Setoguchi K., et al. Peroxisome proliferator-activated receptor-γ haploinsufficiency enhances B cell proliferative responses and exacerbates experimentally induced arthritis. J. Clin. Invest. 108:2001;1667-1675.
63. Bright J.J., et al. Peroxisome proliferator-activated receptor-γ-deficient heterozygous mice develop an exacerbated neural antigen-induced Th1 response and experimental allergic encephalomyelitis. J. Immunol. 171:2003;5743-5750.